The Patent Finder

Terms ending in 2038

Cellectis

Every in-force patent on Cellectis's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 10,836,998Cells for Immunotherapy Engineered for Targeting Antigen Present Both on Immune Cells and Pathological Cells
In force
 · High confidence
CellectisIn forceHigh confidence
US 12,133,867Universal ANTI-CD22 Chimeric Antigen Receptor Engineered Immune Cells
In force
 · High confidence
Cellectis S.A.In forceHigh confidence
US 11,186,824Methods for Engineering Allogeneic T Cell to Increase Their Persistence And/Or Engraftment into Patients
In force
 · High confidence
CellectisIn forceHigh confidence
US 11,820,996Method for Generating T-Cells Compatible for Allogenic Transplantation
In force
 · High confidence
CellectisIn forceHigh confidence
US 11,479,782Alfalfa with Reduced Lignin Composition
In force
 · High confidence
CellectisIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited